Cancer's bite could be reduced by low-dose aspirin

British medical journal Lancet published a new research today. Taking low-dose aspirin for years might decrease the risk of dying from cancer. The study, issued today, reviewed eight previous studies involving 25,500 subjects. While the research is likely, you will find significant gaps and doctors don't immediately recommend starting an aspirin regimen.

Risk of cancer dying seems to mean reduced with aspirin

Today, the meta-study was published. A team or researchers in Britain published them. They found that 75 milligrams of aspirin were taken regular for five years or more reduce the chance of dying from cancer. Deaths from lung and prostate cancer did reduce about 20 percent, gastrointestinal cancers by 54 percent and esophageal tumors by 60 percent. These benefits appeared after regular low-dose aspirin had done taken for between five and 20 years. The studies had initially been intended to check out the cardiovascular effects of taking daily aspirin.

Is not a good idea to start taking aspirin day-to-day

There was a dramatic improvement with those surviving cancers with the drug. However, it is not suggested that you do it regular still. This meta-study considered a relatively small number of subjects, and more research needs to do carried as "proof of principle.". It would remain relatively safe to take aspirin daily. Of course, ringing in the ears, loss of balance, heartburn and thinning of blood can occur with it too. "I surely think we wouldn't want in making any employment decisions depending on this research," said Dr. Raymond DuBois, a supervisor at the University of TX M.D. Anderson Cancer Center.

Problems with the aspirin-cancer study

Problems with the aspirin-cancer study

The same group of British researchers did both studies that showed the link between aspirin and improved cancer success rates. The studies aren’t complete, though. You will find gaps in them. Out of the 25,500 people in the main meta-analysis, only 33 percent were women. Additionally, data was absent on the impact of taking low-dose aspirin on less-common cancers, such as brain and abdomen cancer. The group of patients may obtain statistically skewed since the benefit of aspirin on the heart was what the studies were first going on.

In the end, this aspirin cancer link is an exciting and possibly useful one, but there is not nearly enough research yet to safely recommend it as a treatment for a lot of people.